SLC7A11 and prostate cancer: Our study found that palbociclib affects the cellular iron and GSH content through TRIB3/SOX2/SLC7A11 signaling axis, disrupting the cellular redox balance and promoting ferroptosis in prostate cancer cells (Fig. 7).